

Ref: 001/BSE/June 2023

June 28, 2023

To,  
The Manager,  
Listing Department,  
Bombay Stock Exchange Limited,  
Phiroze Jeejeebhoy Towers,  
Dalal Street, Fort, Mumbai- 400001

**Sub: Disclosure under Regulation 29(1) of SEBI (Substantial Acquisition of Shares and Takeovers) Regulations, 2011**

**Ref: Symbol: 543245, Gland Pharma Limited, (ISIN: INE068V01023)**

Dear Sir/Madam,

With reference to the above captioned matter, please find enclosed herewith, disclosure under Regulation 29 (1) of SEBI (Substantial Acquisition of Shares and Takeovers) Regulations, 2011 for the acquisition made on June 27, 2023.

You are requested to take the same on your records.

Thanking you.

Yours faithfully,  
**For Mirae Asset Investment Managers (India) Private Limited**



**Rimmi Jain**  
**Compliance Officer**  
Encl: As above

CC:  
**GLAND PHARMA LIMITED**  
SY.NO.143-148,150 &151,  
NEAR GANDI MAISAMMA X ROADS D.P.PALLY,  
DUNDIGAL, DUNDIGAL - GANDIMASAMMA(M) MEDCHAL MALKAJGIRI  
DISTRICT HYDERABAD TG 500043 IN

**ANNEXURE - 1**

**Format for Disclosures under Regulation 29(1) of SEBI (Substantial Acquisition of Shares and Takeovers) Regulations, 2011**

**Part-A- Details of the Acquisition**

Name of the Target Company (TC)	Gland Pharma Limited		
Name(s) of the acquirer and Persons Acting in Concert (PAC) with the acquirer	Mirae Asset Mutual Fund		
Whether the acquirer belongs to Promoter/Promoter group	No		
Name(s) of the Stock Exchange(s) where the shares of TC are Listed	National Stock Exchange of India Ltd. BSE Ltd.		
Details of the acquisition as follows	Number	% w.r.t. total share/voting capital wherever applicable(*)	% w.r.t. total diluted share/voting capital of the TC (**)
<b>Before the acquisition under consideration, holding of acquirer along with PACs of:</b>			
a) Shares carrying voting rights	8200711	4.98	4.98
b) Shares in the nature of encumbrance (pledge/ lien/ non-disposal undertaking/ others)			
c) Voting rights (VR) otherwise than by equity shares			
d) Warrants/convertible securities/any other instrument that entitles the acquirer to receive shares carrying voting rights in the TC (specify holding in each category)			
e) Total (a+b+c+d)			
	8200711	4.98	4.98
<b>Details of acquisition</b>			
a) Shares carrying voting rights acquired	53501	0.03	0.03
b) VRs acquired otherwise than by equity shares			
c) Warrants/convertible securities/any other instrument that entitles the acquirer to receive shares carrying			

*Rain*

category) acquired d) Shares in the nature of encumbrance (pledge/ lien/ non-disposal undertaking/ others) e) Total (a+b+c+/-d)	53501	0.03	0.03
<b>After the acquisition, holding of acquirer along with PACs of:</b>			
a) Shares carrying voting rights b) VRs otherwise than by equity shares c) Warrants/convertible securities/any other instrument that entitles the acquirer to receive shares carrying voting rights in the TC (specify holding in each category) after acquisition d) Shares in the nature of encumbrance (pledge/ lien/ non-disposal undertaking/ others) e) Total (a+b+c+d)	8254212	5.01	5.01
	8254212	5.01	5.01
Mode of acquisition (e.g. open market / public issue / rights issue / preferential allotment / inter-se transfer/encumbrance, etc.)	Open Market		
Salient features of the securities acquired including time till redemption, ratio at which it can be converted into equity shares, etc.	NA		
Date of acquisition of/ date of receipt of intimation of allotment of shares / VR/ warrants/convertible securities/any other instrument that entitles the acquirer to receive shares in the TC.	27/06/2023		
Equity share capital / total voting capital of the TC before the said acquisition	16,47,00,823		
Equity share capital/ total voting capital of the TC after the said acquisition	16,47,00,823		
Total diluted share/voting capital of the TC after the said acquisition	16,47,00,823		

*R Jain*